Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)
GlucoTrack, Inc. (NASDAQ:GCTK) announced a $10 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner on April 17, 2023. The funds are intended to support the company's mission of developing non-invasive glucose monitoring devices for diabetes patients. Founded in 2001 and based in Or Yehuda, Israel, GlucoTrack is focused on providing an alternative to traditional glucose measurement methods, thereby improving the quality of life for diabetics and pre-diabetics. The company aims to enhance its product offerings and expand its market reach with the new capital raised from this offering.
- The $10 million funding aims to bolster the development of non-invasive glucose monitoring technology.
- Potential to expand market reach and product offerings for diabetes management.
- None.
NEW YORK, NY / ACCESSWIRE / April 17, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a
About GlucoTrack, Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
For more information, please visit: https://www.glucotrack.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/749539/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-10-Million-Underwritten-Public-Offering-for-GlucoTrack-Inc-NASDAQ-GCTK
FAQ
What is the purpose of GlucoTrack's $10 million public offering?
Who acted as the sole bookrunner for GlucoTrack's offering?
When was the public offering for GlucoTrack announced?
How will the funds from the public offering impact GCTK's future?
